PubMed Health⌕ Search

Biomedical subjects

J R Schuh

Publications and source records attributed to J R Schuh.

14 recordsLinked to original sources
PubMed1993

Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits.

To investigate the mechanism by which angiotensin-converting enzyme (ACE) inhibition attenuates atherogenesis, we have studied the effects of a non-sulfhydryl ACE inhibitor, enalapril, and an angiotensin receptor antagonist, SC-51316, in cholesterol-fed rabbits. After 3 mo of enalapril treatment (10 mg/kg per d, p.o.) the percent plaque areas in the thoracic aortas of treated animals were significantly reduced (controls: 86.8 +/- 3.5%; treated: 31.1 +/- 8%, P < 0.001). Aortic cholesterol content was also reduced (controls: 31.4 +/- 3.2 mg/g tissue; treated: 7.4 +/- 1.8 mg/g, P < 0.001). Enalapril had no significant effect on plasma lipid levels or conscious blood pressure. In a second study, the angiotensin II receptor antagonist SC-51316 was administered at a dose equivalent to enalapril at blocking angiotensin pressor effects in vivo (30 mg/kg per d, p.o.). Evaluation after 3 mo indicated no significant attenuation of aortic atherosclerosis. These results demonstrate that: (a) enalapril attenuates atherogenesis without affecting either blood pressure or plasma lipid levels; (b) antioxidant activity, found with sulfhydryl-containing ACE inhibitors, is not necessary for reducing plaque formation; and (c) the attenuation of atherogenesis by ACE inhibition may not be due to blockade of the renin-angiotensin system. Alternatively, one must consider the multiple effects of ACE inhibition on other hormone systems, such as bradykinin, or the possibility that alternate angiotensin II receptors may be involved in atherosclerosis.

Angiotensin Receptor Antagonists↗
PubMed1992

In vitro pharmacology of a nonpeptidic angiotensin II receptor antagonist, SC-51316.

The properties of a novel nonpeptidic angiotensin II (AII) receptor antagonist, 2,5-dibutyl-2,4-dihydro-4-([2-(1H-tetrazol-5-yl)(1,1'-biphenyl) -4'-yl]methyl)-3H-1,2,4-triazol-3-one (SC-51316), are described. SC-51316 inhibited [125I]AII binding selectively to the AT1 receptor with IC50 values of 3.6 and 5.1 nM in rat adrenal cortical and rat uterine membrane preparations, respectively. The compound was a competitive and reversible antagonist of AII-mediated contraction of rabbit aortic rings with a pA2 of 8.86. In addition, SC-51316 inhibited AII-induced aldosterone release from rat adrenal zona glomerulosa cells and blocked inhibition of renin release by AII from rat kidney slices with pA2 values of 8.62 and 8.9, respectively. The agent (0.1 mM) did not inhibit angiotensin-converting enzyme or plasma renin activity. These data demonstrate that SC-51316 is a potent AII receptor antagonist which may prove to be useful as a pharmacologic tool for studying the role of the renin-angiotensin system in cardiovascular diseases.

Adrenal Cortex↗
PubMed1990

Central and peripheral actions of a nonpeptidic angiotensin II receptor antagonist.

Nonpeptidic imidazole derivatives were recently reported to be angiotensin II receptor antagonists with acute blood pressure-lowering activity. In the present study, we characterized the angiotensin II receptor antagonist properties of one such derivative, 4'-([2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl)- [1,1'-biphenyl]-2-carboxylic acid (IMI). In receptor binding studies, IMI displaced bound [125I]angiotensin II from rat uterine membranes with an IC50 of 0.17 microM. In isolated rabbit aortic rings, IMI shifted the angiotensin II concentration-response curve to the right in a parallel and concentration-dependent manner. A Schild plot of these data indicated a pA2 of 7.13 +/- 0.16 and a slope of 0.94 +/- 0.06. In rat kidney slices, IMI shifted the concentration-response curve for angiotensin II-induced inhibition of renin release to the right. Antagonism of the angiotensin II pressor response by IMI was dose dependent and reversible in ganglion-blocked, anesthetized rats. The water intake and pressor responses to intracerebroventricular angiotensin II (100 pmol) were inhibited by intracerebroventricular IMI (25 or 50 nmol) in conscious Sprague-Dawley rats. Similarly, the drinking and pressor responses to intravenous angiotensin II were blocked by intravenous IMI in conscious rats. IMI alone had no effects on mean arterial pressure or drinking when administered either intravenously or intracerebroventricularly. IMI decreased mean arterial pressure throughout 5 days of infusion in spontaneously hypertensive rats. In summary, IMI was a full competitive antagonist without partial agonist activity in peripheral tissues and the central nervous system. Moreover, the chronic administration of this angiotensin II receptor antagonist was antihypertensive in spontaneously hypertensive rats.

Angiotensin II↗
PubMed1990

Chronic atriopeptin regulation of arterial pressure in conscious hypertensive rats.

Acute coadministrations of an inhibitor of endopeptidase 24.11 (thiorphan) and a ligand (SC-46542) selective for the non-guanylate cyclase-linked atriopeptin binding sites increases urinary sodium excretion to a greater degree in conscious spontaneously hypertensive rats than in normotensive Wistar-Kyoto rats. In the present study, we examined the effects of chronic 10-day intravenous infusions of SC-46542 (des[Phe106,Gly107,Ala115,Gln116] atriopeptin-(103-126] (0.1 mg/kg/hr), thiorphan (1.5 mg/kg/hr), and atriopeptin-(103-126) (100 ng/hr) alone or in combination on direct recording of mean arterial pressure in conscious spontaneously hypertensive rats. During an 11-day time-control infusion of isotonic saline vehicle (100 microliters/hr), mean arterial pressure remained stable. Chronic infusion of atriopeptin-(103-126) decreased mean arterial pressure progressively over the first 3 days; then mean arterial pressure progressively rose to control level over the following 3 days and remained at control level for the remainder of the experiment. Similarly, coinfusions of atriopeptin-(103-126) and SC-46542 or thiorphan, SC-46542 and thiorphan, or the triple infusion of atriopeptin-(103-126), SC-46542, and thiorphan had only transient effects on mean arterial pressure during 10-day infusions. SC-46542 alone had no effect on mean arterial pressure. Similarly, thiorphan alone had no effect on mean arterial pressure except at doses that blocked the acute pressor response to angiotensin I. Chronic infusions of atriopeptin-(103-126), SC-46542, and thiorphan alone or in combination are not effective long-term treatments for hypertension in spontaneously hypertensive rats.

Animals↗
PubMed1985

Modification of vesicle surfaces with amphiphilic sterols. Effect on permeability and in vivo tissue distribution.

In this paper, we describe the permeability of vesicles prepared with various synthetic cholesterol derivatives. Cholesterol derivatives with side-chains ending in hydroxyl groups reduced the permeability of unilamellar vesicles. However, addition of cholesterol derivatives with terminal amino groups makes the vesicles more permeable. Vesicles prepared with a short-chain amino-cholesterol derivative were found to be less permeable in phosphate-buffered saline, but not in bovine serum, while long-chain amino-cholesterol-containing vesicles were very permeable in both media. Studies in vivo indicate a rapid clearance rate for intravenously administered amino-cholesterol-containing vesicles with a concomitant increase in liver uptake. However, no difference was found in either the clearance or tissue distribution of control vesicles and the less permeable hydroxyl-cholesterol-containing vesicles.

Animals↗
PubMed1984

The pharmacological efficacy of a rigid non-phospholipid liposome drug delivery system.

Hydration of an ethoxylate derivative of cholesterol, triethoxycholesterol, results in the formation of stable, rigid, bilayer-like structures capable of encapsulating polar compounds. Studies on the stability and tissue distribution of these liposomes in mice indicate that they are suitable as a drug delivery system. Intraperitoneal injection of triethoxycholesterol encapsulated methotrexate into mice bearing hepatoma ascites tumor results in a doubling of the survival time, relative to untreated mice and those receiving unencaptulated drug. These studies show that fluid, acyl chains are not required for the formation of pharmacologically useful vesicles and that such formulations need not be limited to phospholipid-containing systems.

Animals↗
PubMed1982

The phospholipid packing arrangement in small bilayer vesicles as revealed by proton magnetic resonance studies at 500 MHz.

Proton magnetic resonance spectra of saturated phospholipids in small unilamellar vesicles has been recorded at 500 MHz on a Bruker WM500 spectrometer. The additional spectral dispersion reveals new structure in the acyl chain resonances. At temperatures near the thermal phase transition, the chain methylene and methyl peaks are split, both showing a broad and a relatively sharp component. Magnetization transfer experiments together with studies in the presence of manganese ions inside or outside the vesicles indicate that the sharp component is to be assigned to the protons from the acyl chains in the inner half of the bilayer and the broad component to chains in the outer monolayer. These experiments demonstrate unambiguously that the extreme surface curvature intrinsic to small unilamellar vesicles induces a profound asymmetry in the packing arrangement of the hydrocarbon chains in the two leaflets of the bilayer and causes the two monolayers to exist in markedly different motional states.

Aged↗
PubMed1982

Stability of carbohydrate-modified vesicles in vivo: comparative effects of ceramide and cholesterol glycoconjugates.

The stability and tissue distribution of lipid vesicles modified at the surface by the incorporation of either a galactosyl ceramide (GalCer) or a galactosyl cholesterol (GalChol) glycoconjugate have been studied in mice by measuring the release of vesicle-entrapped 111In. Although the tissue distributions of both vesicle types were similar, the GalCer-containing vesicles were markedly less stable than those prepared with GalChol, whether administered orally or by intraperitoneal injection. Physical characterization of the vesicles in vitro suggests that the increased disruption rate for GalCer vesicles in vivo is related to structural instabilities induced by the cerebroside, which can then result in either an increased rate of vesicle uptake by tissues or a greater susceptibility to lysis. These studies demonstrate the importance of the nonpolar anchoring groups in determining the fate of surface-modified vesicles in vivo.

Administration, Oral↗
PubMed1981

Huntington disease and Tourette syndrome. I. Electron spin resonance of bed ghosts.

Abnormalities in the electron spin resonance (ESR) of nitroxide-labeled red blood cell membranes have been reported in Huntington disease (HD). Because of the importance of verifying a general membrane defect in this disease, we have examined 13 unmedicated HD patients of all grades of severity, with a duration of symptoms from 3 to 20 years and including juvenile and rigid cases. No significance differences in the ESR of controls, HD patients, and three Tourette syndrome patients were found.

Adolescent↗
PubMed1980

Lipoprotein uptake in perfused arteries: inhibition by 7-ketocholesterol.

The effect of 7-Ketocholesterol (7-KC), an oxygenated sterol (OS) on the uptake of low density lipoproteins (LDL) by artificially perfused porcine carotid arteries was studied. The perfusate consisted of Dulbecco's modified Eagle medium, supplemented with albumin and pure 125I-LDL. Prior exposure to 7-KC significantly inhibited LDL uptake (from 2.47 to 1.92 micrograms LDL p/gr artery). The degree of inhibition of LDL uptake was less than that previously observed for arterial influx of cholesterol.

Animals↗